227 related articles for article (PubMed ID: 29636685)
1. Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.
Menzel S; Schwarz N; Haag F; Koch-Nolte F
Front Pharmacol; 2018; 9():266. PubMed ID: 29636685
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models
Demeules M; Scarpitta A; Hardet R; Gondé H; Abad C; Blandin M; Menzel S; Duan Y; Rissiek B; Magnus T; Mann AM; Koch-Nolte F; Adriouch S
Front Immunol; 2022; 13():1012534. PubMed ID: 36341324
[TBL] [Abstract][Full Text] [Related]
3. A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7
Gondé H; Demeules M; Hardet R; Scarpitta A; Junge M; Pinto-Espinoza C; Varin R; Koch-Nolte F; Boyer O; Adriouch S
Front Immunol; 2021; 12():704408. PubMed ID: 34489954
[TBL] [Abstract][Full Text] [Related]
4. Development of Antibody and Nanobody Tools for P2X7.
Stähler T; Danquah W; Demeules M; Gondé H; Hardet R; Haag F; Adriouch S; Koch-Nolte F; Menzel S
Methods Mol Biol; 2022; 2510():99-127. PubMed ID: 35776322
[TBL] [Abstract][Full Text] [Related]
5. Nanobodies as probes to investigate purinergic signaling.
Eggers M; Rühl F; Haag F; Koch-Nolte F
Biochem Pharmacol; 2021 May; 187():114394. PubMed ID: 33388283
[TBL] [Abstract][Full Text] [Related]
6. [Progress on role of extracellular ATP and its metabolite adenosine in immunoregulation: Review].
Wang C; Yin Q; Su Z; Xia L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Dec; 36(12):1134-1140. PubMed ID: 33325366
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD
Baum N; Fliegert R; Bauche A; Hambach J; Menzel S; Haag F; Bannas P; Koch-Nolte F
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396591
[TBL] [Abstract][Full Text] [Related]
8. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.
Deaglio S; Robson SC
Adv Pharmacol; 2011; 61():301-32. PubMed ID: 21586363
[TBL] [Abstract][Full Text] [Related]
9. Divergent regulatory roles of extracellular ATP in the degranulation response of mouse bone marrow-derived mast cells.
Yoshida K; Ito M; Matsuoka I
Int Immunopharmacol; 2017 Feb; 43():99-107. PubMed ID: 27988461
[TBL] [Abstract][Full Text] [Related]
10. Purine Release, Metabolism, and Signaling in the Inflammatory Response.
Linden J; Koch-Nolte F; Dahl G
Annu Rev Immunol; 2019 Apr; 37():325-347. PubMed ID: 30676821
[TBL] [Abstract][Full Text] [Related]
11. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
12. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
[TBL] [Abstract][Full Text] [Related]
13. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.
de Andrade Mello P; Coutinho-Silva R; Savio LEB
Front Immunol; 2017; 8():1526. PubMed ID: 29184552
[TBL] [Abstract][Full Text] [Related]
14. Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation.
Danquah W; Meyer-Schwesinger C; Rissiek B; Pinto C; Serracant-Prat A; Amadi M; Iacenda D; Knop JH; Hammel A; Bergmann P; Schwarz N; Assunção J; Rotthier W; Haag F; Tolosa E; Bannas P; Boué-Grabot E; Magnus T; Laeremans T; Stortelers C; Koch-Nolte F
Sci Transl Med; 2016 Nov; 8(366):366ra162. PubMed ID: 27881823
[TBL] [Abstract][Full Text] [Related]
15. Purinergic signaling during intestinal inflammation.
Longhi MS; Moss A; Jiang ZG; Robson SC
J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
[TBL] [Abstract][Full Text] [Related]
16. Novel biologics targeting the P2X7 ion channel.
Koch-Nolte F; Eichhoff A; Pinto-Espinoza C; Schwarz N; Schäfer T; Menzel S; Haag F; Demeules M; Gondé H; Adriouch S
Curr Opin Pharmacol; 2019 Aug; 47():110-118. PubMed ID: 30986625
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities.
Bortell R; Moss J; McKenna RC; Rigby MR; Niedzwiecki D; Stevens LA; Patton WA; Mordes JP; Greiner DL; Rossini AA
J Immunol; 2001 Aug; 167(4):2049-59. PubMed ID: 11489987
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the expression and function of the P2X7 receptor and ART1 in human regulatory T-cell subsets.
Cortés-Garcia JD; López-López C; Cortez-Espinosa N; García-Hernández MH; Guzmán-Flores JM; Layseca-Espinosa E; Portales-Cervantes L; Portales-Pérez DP
Immunobiology; 2016 Jan; 221(1):84-93. PubMed ID: 26307000
[TBL] [Abstract][Full Text] [Related]
19. Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis.
Jalkanen J; Yegutkin GG; Hollmén M; Aalto K; Kiviniemi T; Salomaa V; Jalkanen S; Hakovirta H
Circ Res; 2015 Mar; 116(7):1206-15. PubMed ID: 25645301
[TBL] [Abstract][Full Text] [Related]
20. Adenine nucleotides as paracrine mediators and intracellular second messengers in immunity and inflammation.
Fliegert R; Heeren J; Koch-Nolte F; Nikolaev VO; Lohr C; Meier C; Guse AH
Biochem Soc Trans; 2019 Feb; 47(1):329-337. PubMed ID: 30674608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
